« back to GLOBAL TRANSPARENCY PAGE

Romania
transparency obligations overview

Last reviewed: January 2024 | Important Notes
PHARMACEUTICAL
MEDICAL DEVICE

 

Pharmaceutical Companies

Code:

What is reported:

Transfers of value related to:

  • Sponsorships/Donations/Grants
  • Contribution to event-related costs
  • Fees for Services and Consultancy
  • Research and development

*As the first 3 ToV are covered by the law, only the Research and Development ToV need to be reported under the Code, as far as we understand.

Law:

What is reported:

“It is mandatory that manufacturers, MAH or their representatives to Romania as well as wholesale and retail distributors notify the NAMMDR, before 31 March of the current year, all sponsoring activities as well as any other expenses undertaken the previous year, provided to healthcare professionals, patient organisations and any other type of organisations conducting healthcare activities, medical or pharmaceutical care.”

“Notification of sponsoring activities and other expenses, other than sponsoring, conducted as per paragraphs (3) and (4) shall be performed in line with the templates as provided in Annexes 1 and 2 to these Rules.”

Medical Device Companies

What is reported:

According to Order of the Minister of Health no. 874/2015 Manufacturers or their representatives in Romania as well as wholesale and retail distributors for medical devices and sanitary materials must notify the Ministry of Health, through its specialty structure ANDMR – the competent authority in medical devices field, before 31 March of the current year, all sponsoring activities as well as any other expenses undertaken the previous year, provided to physicians, nurses, professional associations, patient organisations and any other type of organisations conducting healthcare activities, medical or pharmaceutical care.

‘The templates for reporting the activities set out at Art.1 are included in the Annexes 1 and 2, which form an integral part of this order.’

MedTech Code

If your company is a member of MedTech Europe, disclosure should be done in line with the Disclosure Guidelines of the MedTech Europe Code of Ethical Business Practice (see part 2). The summary is provided here: link

In 2018 AFPM (Romanian Medical Products Suppliers Association) adopted the MedTech Europe Code as its Code of Ethics. AFPM is currently discussing how to implement the new Code.

The summary provided here is based on the Romanian law.

What is reported:

All sponsorship activities and any other costs covered for HCPs, patients’ organisations and other healthcare organisations

 

Important notes:

  • This information is provided for your convenience and should not be construed as legal advice. The applicability of these requirements to your organization depends on individual circumstances. The information is not exhaustive.
  • Kindly check with your legal department and do not depend solely on the information provided here. Moreover, the rules mentioned could be subject to interpretation of local authorities/courts in the applicable jurisdiction. Lastly, be mindful of the latest update mentioned above. These rules and regulations change frequently, so it is important to determine whether the information provided reflects the most recent changes and is still applicable.
  • Reporting dates are related to the transparency obligation regarding transfers of value by pharmaceutical companies and/or medical device companies (excluding – in most cases – suppliers of in vitro diagnostics) to HCPs and HCOs. These often are based on laws or rules in codes of conduct of industry associations. In case it is based on codes of conduct, your company only needs to disclose the transfers of value on the mentioned due date if your company is a member of the association that follows that code.
  • Including a jurisdiction in the Legislative Watch does not guarantee that jurisdiction is available for reporting via the MediSpend Transparency Reporting Solution.
  • Reporting date normally means the date the transfers of value need to be published. The deadline for e.g. submission/sending the complete information to the authority could be before that date, for example to give HCPs and/or HCOs and/or the authority/association who publishes the information, the possibility to check the data the pharmaceutical companies/medical device companies are going to disclose.
  • The information does not take into consideration (unless explicitly mentioned):
    • Transparency related to clinical trials (unless it concerns transfers of value as mentioned above)
    • Transparency related to patient organizations (unless the patient organization is considered an HCO)


Disclaimer:

The information contained in this website is for general information purposes only. The information is provided by MediSpend and, while we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is, therefore, strictly at your own risk.

In no event will MediSpend be liable for any loss or damage including, without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

Through this website you may be able to link to other websites which are not under the control of MediSpend. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Every effort is made to keep the website up and running smoothly. However, MediSpend takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.